Complete data demonstrating a new medicine can slow cognitive deterioration
in Alzheimer’s patients were released on Wednesday, which was met with
expert praise. However, they cautioned that the improvements were modest
and the treatment could have significant side effects.
It was reported in September that lecanemab, in an early clinical trial,
reduced the rate of cognitive deterioration by 27 percent over 18 months.
New England Journal of Medicine’s publication of the complete study data
supports these conclusions. Still, it raises new questions regarding the
frequency of “adverse events,” such as bleeding and swelling in the brain.
in Alzheimer’s patients were released on Wednesday, which was met with
expert praise. However, they cautioned that the improvements were modest
and the treatment could have significant side effects.
It was reported in September that lecanemab, in an early clinical trial,
reduced the rate of cognitive deterioration by 27 percent over 18 months.
New England Journal of Medicine’s publication of the complete study data
supports these conclusions. Still, it raises new questions regarding the
frequency of “adverse events,” such as bleeding and swelling in the brain.
